Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

A new study has found older-looking brains in adults with sickle cell disease, helping to explain the cognitive challenges experienced by such individuals. A brain image from a healthy individual ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

CRISPR Therapeutics is a mid-stage biotech specializing in gene editing. The company has just one product on the market, ...